Business Description
abrdn Life Sciences Investors
NAICS : 523940
SIC : 6282
ISIN : US87911K1007
Share Class Description:
HQL: CE with IsEquityFundamentalDataAvailable = 1 in GidDescription
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | N/A |
N/A
|
N/A
| |||
Equity-to-Asset | 1 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Book Growth Rate | 3.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.73 | |||||
9-Day RSI | 42.4 | |||||
14-Day RSI | 49.38 | |||||
3-1 Month Momentum % | 9.81 | |||||
6-1 Month Momentum % | 12.97 | |||||
12-1 Month Momentum % | 44.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 10.53 | |||||
Dividend Payout Ratio | 0.29 | |||||
3-Year Dividend Growth Rate | 7.4 | |||||
Forward Dividend Yield % | 10.53 | |||||
5-Year Yield-on-Cost % | 11.97 | |||||
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | 10.58 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Net Margin % | 99.62 | |||||
FCF Margin % | 20.01 | |||||
OCF Margin % | 20.01 | |||||
ROE % | 40.43 | |||||
ROA % | 39.9 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.92 | |||||
PE Ratio without NRI | 2.92 | |||||
PS Ratio | 3.16 | |||||
PB Ratio | 1.05 | |||||
Price-to-Tangible-Book | 1.05 | |||||
Price-to-Free-Cash-Flow | 15.63 | |||||
Price-to-Operating-Cash-Flow | 15.63 | |||||
EV-to-Revenue | 2.96 | |||||
EV-to-FCF | 14.79 | |||||
Price-to-GF-Value | 0.31 | |||||
Price-to-Projected-FCF | 1.31 | |||||
Price-to-Graham-Number | 0.37 | |||||
FCF Yield % | 6.76 | |||||
Forward Rate of Return (Yacktman) % | -3.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:HQL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
abrdn Life Sciences Investors Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 198.925 | ||
| EPS (TTM) ($) | 6.638 | ||
| Beta | 0.8328 | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 20.84 | ||
| 14-Day RSI | 49.38 | ||
| 14-Day ATR ($) | 0.477541 | ||
| 20-Day SMA ($) | 19.953 | ||
| 12-1 Month Momentum % | 44.74 | ||
| 52-Week Range ($) | 13.01 - 21.32 | ||
| Shares Outstanding (Mil) | 30.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
abrdn Life Sciences Investors Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
abrdn Life Sciences Investors Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-08 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-06-08 | 16.92 (-1.91%) | ||
| General meeting for 2026 | 2026-05-27 12:00 | 17.37 (+0.87%) | ||
| USD 0.560000 Cash Dividend | 2026-05-21 | 17.66 (+1.09%) | ||
| USD 0.560000 Cash Dividend | 2026-02-20 | 17.43 (-0.11%) | ||
| Annual report for 2025 | 2025-12-08 | 17.10 (-1.10%) | ||
| USD 0.500000 Cash Dividend | 2025-11-21 | 16.84 (-3.50%) | ||
| USD 0.420000 Cash Dividend | 2025-08-22 | 14.05 (+0.72%) | ||
| Second quarter earnings results for 2025 | 2025-06-09 | 12.81 (+1.26%) | ||
| General meeting for 2025 | 2025-05-28 12:30 | 12.35 (-0.64%) |
Show
Entries
abrdn Life Sciences Investors Frequently Asked Questions
What is abrdn Life Sciences Investors(HQL)'s stock price today?
The current price of HQL is $19.37. The 52 week high of HQL is $21.32 and 52 week low is $13.01.
When is next earnings date of abrdn Life Sciences Investors(HQL)?
The next earnings date of abrdn Life Sciences Investors(HQL) is 2026-12-08 Est..
Does abrdn Life Sciences Investors(HQL) pay dividends? If so, how much?
The Dividend Yield %  of abrdn Life Sciences Investors(HQL) is 10.53% (As of Today), Highest Dividend Payout Ratio of abrdn Life Sciences Investors(HQL) was 1.62. The lowest was 0.29. And the median was 0.63. The  Forward Dividend Yield % of abrdn Life Sciences Investors(HQL) is 10.53%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:HQL
No articles.
Press Release
Articles on abrdn Life Sciences Investors
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers